430 related articles for article (PubMed ID: 2685654)
21. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
23. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal transit of Sinemet CR in healthy volunteers.
Wilding IR; Davis SS; Melia CD; Hardy JG; Evans DF; Short AH; Sparrow RA
Neurology; 1989 Nov; 39(11 Suppl 2):53-8. PubMed ID: 2685651
[TBL] [Abstract][Full Text] [Related]
25. Sustained release antiparkinson agents: controlled release levodopa.
Gauthier S; Amyot D
Can J Neurol Sci; 1992 Feb; 19(1 Suppl):153-5. PubMed ID: 1571861
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
28. The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Rodnitzky RL
Neurology; 1992 Jan; 42(1 Suppl 1):44-50; discussion 57-60. PubMed ID: 1549201
[TBL] [Abstract][Full Text] [Related]
29. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
[TBL] [Abstract][Full Text] [Related]
30. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
31. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of sustained dopaminergic stimulation.
Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
[TBL] [Abstract][Full Text] [Related]
33. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
34. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
Hutton JT; Albrecht JW; Román GC; Kopetzky MT
Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
36. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
40. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]